On Monday, BioAtla Inc (NASDAQ: BCAB) opened lower -4.31% from the last session, before settling in for the closing price of $2.09. Price fluctuations for BCAB have ranged from $1.14 to $4.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -56.91% over the last five years. Company’s average yearly earnings per share was noted 34.41% at the time writing. With a float of $39.01 million, this company’s outstanding shares have now reached $48.08 million.
The firm has a total of 65 workers. Let’s measure their productivity. In terms of profitability, gross margin is 35.11%, operating margin of -6446.95%, and the pretax margin is -6128.72%.
BioAtla Inc (BCAB) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioAtla Inc is 19.30%, while institutional ownership is 40.47%. The most recent insider transaction that took place on Dec 26 ’23, was worth 9,320. In this transaction Director of this company bought 4,000 shares at a rate of $2.33, taking the stock ownership to the 15,125 shares. Before that another transaction happened on Dec 20 ’23, when Company’s Chief Executive Officer bought 50,000 for $2.14, making the entire transaction worth $106,910. This insider now owns 1,439,283 shares in total.
BioAtla Inc (BCAB) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 34.41% per share during the next fiscal year.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
Check out the current performance indicators for BioAtla Inc (BCAB). In the past quarter, the stock posted a quick ratio of 3.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.50 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
Analysing the last 5-days average volume posted by the [BioAtla Inc, BCAB], we can find that recorded value of 0.64 million was lower than the volume posted last year of 0.83 million. As of the previous 9 days, the stock’s Stochastic %D was 50.09%. Additionally, its Average True Range was 0.15.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 68.25%, which indicates a significant increase from 51.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.79% in the past 14 days, which was lower than the 97.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.87, while its 200-day Moving Average is $2.14. Now, the first resistance to watch is $2.10. This is followed by the second major resistance level at $2.20. The third major resistance level sits at $2.25. If the price goes on to break the first support level at $1.95, it is likely to go to the next support level at $1.90. Now, if the price goes above the second support level, the third support stands at $1.80.
BioAtla Inc (NASDAQ: BCAB) Key Stats
There are currently 48,336K shares outstanding in the company with a market cap of 105.23 million. Presently, the company’s annual sales total 0 K according to its annual income of -123,460 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,070 K.
